
BioNTech SE**Report of the Supervisory Board on the 2019
Financial Year**

In the past financial year, the Supervisory Board continuously monitored and advised the Management Board on the management of the Company. During the reporting period, the Management Board regularly and comprehensively informed the Supervisory Board in writing and orally about the situation of the Company as well as about corporate policy and significant business transactions. The development of the Company was discussed together with the Management Board during a total of nine Supervisory Board meetings in the 2019 financial year, i.e. on 20 February 2019, 25 March 2019, 3 May 2019, 13 June 2019, 19 June 2019, 20 August 2019, 11 September 2019, 25/26 November 2019 and 18 December 2019. In addition, telephone calls, telephone conferences and personal meetings were held on a regular basis. During the reporting period, the discussions focused in particular on the status quo of the various collaboration projects, the ongoing expansion efforts at the Mainz, Idar-Oberstein and Berlin sites, the securing of the Company's financing, in particular through capital increases in the context of the Series B financing round, the measures in the run-up to and implementation of the IPO on NASDAQ, the status of the research and development activities and the strategic orientation of BioNTech SE, including its subsidiaries. The development of the current business was also discussed with the Management Board. The Supervisory Board provided advice on important individual issues and transactions requiring its approval. Resolutions were passed by the Supervisory Board both in meetings and by written resolution. All members of the Supervisory Board were present at all meetings.

Committees

The Supervisory Board has formed the following committees: a Capital Markets Committee, an Audit Committee, and a Compensation, Nominating and Corporate Governance Committee. They prepare resolutions and topics to be dealt with in the meetings of the Supervisory Board.

The Capital Market Committee, consisting of the Chairman, Mr. Helmut Jeggle, and Mr. Michael Motschmann, essentially deals with the discussion and examination of strategy options with capital market relevance. The committee met ten times during the financial year. In the year under review, its work focused on supporting the capital increases in the context of the Series B financing round and the IPO on NASDAQ.

An Audit Committee was formed in the 2019 financial year. This committee deals in particular with the monitoring of accounting, the establishment and effective functioning of the internal control system and the risk management system, the SOX implementation project, the monitoring of the establishment and effective functioning of the internal audit system, reporting on the quarterly reports, the preliminary audit of the 2019 German Commercial Code (HGB) and IFRS annual financial statements and the management reports for BioNTech SE and for the group, and the preparation of the resolutions of the Supervisory Board on these points.

At the meeting of the Supervisory Board on 20 February 2019, Dr. Ulrich Wandschneider took over as Chairman, and Mr. Helmut Jeggle and Mr. Michael Motschmann are also members of the Audit Committee. As a member of the Supervisory Board, the Chairman of the Audit Committee, Dr. Ulrich Wandschneider, has expertise in the areas of accounting and auditing as well as special knowledge and experience in the application of internal control procedures. The Audit Committee met five times in 2019.

In addition, a Compensation, Nominating and Corporate Governance Committee was formed at the meeting of the Supervisory Board on 9 September 2020. The members of this committee are Mr. Michael Motschmann as Chairman, Prof. Christoph Huber and Dr. Ulrich Wandschneider. The Remuneration Committee deals with fundamental questions of remuneration and the determination of the salaries of the Management Board and the remuneration of the Supervisory Board (for which proposals are to be submitted to the Annual General Meeting if necessary) and makes proposals to the full Supervisory Board in this regard in the event of new appointments to the Management Board. In doing so, it also takes into account the targets for the composition of the executive bodies, which were defined for the first time in 2019 and renewed in the reporting year. The committee also deals with the development of a corporate governance standard for the Company that complies with both the requirements of NASDAQ and the German Corporate Governance Code. The committee met four times in 2019.

Corporate Governance

As a company based in Germany and listed on NASDAQ, BioNTech voluntarily complies with the German Corporate Governance Code. The Supervisory Board therefore follows the development of the German Corporate Governance Code on an ongoing basis. We will continue to support the Management Board in its efforts to comply fully with the recommendations of the German Corporate Governance Code. The current declaration of conformity pursuant to section 161 of the German Stock Corporation Act (AktG) dated 4 May 2020 attests to full compliance with the recommendations of the German Corporate Governance Code except for the deviations declared. No conflicts of interest of Supervisory Board and Management Board members were reported in the financial year.

Annual Accounts

The annual financial statements for the 2019 financial year prepared by the management Board on 14 May 2020, the consolidated financial statements for 2019 prepared on 14 May 2020, the management report and the group management report were submitted to all members of the Supervisory Board. The audit reports on the accounting, the annual financial statements, the consolidated financial statements and the management reports of the auditors elected by the Annual General Meeting, Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, each of which was issued with an unqualified audit opinion on 14 May 2020, were also made available to us. The auditor's report was discussed in the Audit Committee with the Management Board and the auditors. The report was then discussed by the Supervisory Board.

For its part, the Supervisory Board has examined the annual financial statements for the 2019 financial year, the consolidated financial statements for 2019, the management report and the group management report.

Following the final result of its audit of the annual financial statements and the consolidated financial statements, the Supervisory Board has no objections to raise; it therefore considers the auditor's assessment of the annual financial statements to be correct. We approve the annual financial statements prepared by the Management Board and the consolidated financial statements prepared by the Management Board. The former are thus adopted. The Supervisory Board also agrees with the management reports.

Thanks of the Supervisory Board

The Supervisory Board would like to thank the members of the Management Board and all employees worldwide for their active commitment in the past financial year, as well as the employee representatives for their constructive cooperation with the Company's bodies.

Munich, 15 May 2020

Helmut Jeggle
Chairman of the Supervisory Board